The discovery of these microbially generated FXR inhibitors provides new insights into host–microbe metabolic crosstalk and suggests potential therapeutic strategies for metabolic disorders via targeted intestinal FXR suppression [1]. Here, NR1H4 is linked to Other metabolic disease.